Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

被引：0
作者：
Christian Lehmann
Thomas Friess
Fabian Birzele
Anna Kiialainen
Markus Dangl
机构：
[1] Roche Pharma Research & Early Development,
[2] Roche Innovation Center Munich,undefined
[3] Roche Diagnostics GmbH,undefined
[4] Roche Pharma Research & Early Development,undefined
[5] Roche Innovation Center Basel,undefined
[6] F-Hoffmann-La Roche Ltd,undefined
[7] Present address: Medigene Immunotherapies GmbH,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
BCL-2; MDM2; AML; Cell cycle kinetics; Apoptosis; Idasanutlin; Venetoclax; p53; MCL-1; Synergism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification
    Cornillie, J.
    Wozniak, A.
    Li, H.
    Gebreyohannes, Y. K.
    Wellens, J.
    Hompes, D.
    Debiec-Rychter, M.
    Sciot, R.
    Schoffski, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04) : 546 - 554
  • [32] Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
    Corinne Capoulade
    Brigitte Bressac-de Paillerets
    Isabelle Lefrère
    Muriel Ronsin
    Jean Feunteun
    Thomas Tursz
    Joëlle Wiels
    Oncogene, 1998, 16 : 1603 - 1610
  • [33] Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers
    Katz, Chen
    Low-Calle, Ana Maria
    Choe, Joshua H.
    Laptenko, Oleg
    Tong, David
    Joseph-Chowdhury, Jazmine-Saskya N.
    Garofalo, Francesca
    Zhu, Yan
    Friedler, Assaf
    Prives, Carol
    GENES & DEVELOPMENT, 2018, 32 (5-6) : 430 - 447
  • [34] Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
    Capoulade, C
    Bressac-de Paillerets, B
    Lefrère, I
    Ronsin, M
    Feunteun, J
    Tursz, T
    Wiels, J
    ONCOGENE, 1998, 16 (12) : 1603 - 1610
  • [35] Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia
    Xiong, Xiujuan
    Wang, Min
    Wang, Lin
    Liu, Jiazhuo
    Zhao, Xin
    Tian, Zheng
    Wang, Jianxiang
    LEUKEMIA RESEARCH, 2009, 33 (11) : 1454 - 1458
  • [36] Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells
    Geng, Qian-Qian
    Dong, Dan-Feng
    Chen, Nan-Zheng
    Wu, Yin-Ying
    Li, En-Xiao
    Wang, Jie
    Wang, Shao-Meng
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (06) : 1935 - 1942
  • [37] 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models
    Garg, Ravendra
    Allen, Kevin J. H.
    Dawicki, Wojciech
    Geoghegan, Eileen M.
    Ludwig, Dale L.
    Dadachova, Ekaterina
    CANCER MEDICINE, 2021, 10 (03): : 1128 - 1140
  • [38] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
    Arya, A. K.
    El-Fert, A.
    Devling, T.
    Eccles, R. M.
    Aslam, M. A.
    Rubbi, C. P.
    Vlatkovic, N.
    Fenwick, J.
    Lloyd, B. H.
    Sibson, D. R.
    Jones, T. M.
    Boyd, M. T.
    BRITISH JOURNAL OF CANCER, 2010, 103 (02) : 186 - 195
  • [39] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
    A K Arya
    A El-Fert
    T Devling
    R M Eccles
    M A Aslam
    C P Rubbi
    N Vlatković
    J Fenwick
    B H Lloyd
    D R Sibson
    T M Jones
    M T Boyd
    British Journal of Cancer, 2010, 103 : 186 - 195
  • [40] The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants
    Brown, DR
    Deb, D
    Frum, R
    Hickes, L
    Munoz, R
    Deb, S
    Deb, SP
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (03) : 449 - 459
12345